RP-HPLC Method for Simultaneously Quantifying the Antiviral Drug Contents of Acyclovir, Amantadine, and Oseltamivir in Pharmaceutical Formulations

Abstract

Antibiotics treat bacterial infections, whereas antiviral drugs treat viral illnesses. Antivirals are used to treat a variety of infectious diseases, including COVID-19 and influenza. The technique of reversed-phase high-performance liquid chromatography (RP-HPLC) provides more sensitivity and precision than other approaches, particularly spectrophotometric. This research seeks to develop a simple method for simultaneously quantifying acyclovir, amantadine, and oseltamivir in creams and capsules. The RP-HPLC method optimization and development for verifying the separation and quantification of three antiviral drugs included the investigation of the optimal buffer concentration, pH value, and acetonitrile content. On a C8 HyperClone BDS column, the RP-HPLC system with UV detection achieved separation (250 x 4.60 mm, 130A, and 5). The mixture of acetonitrile and acetate buffer as mobile phase gradient elution at a detection wavelength of 254 nm and 1 mL/min flow rate. The proposed method provided a linear range of 0.08-10.5, 0.06-4.5 and 0.02-14 μg/mL, as well as excellent validated values for LOD (0.0205, 0.0107, and 0.0083 μg/mL) and LOQ (0.0621, 0.0324 and 0.0251 μg/mL) with a coefficient of determination (r2) of the regression line of 0.9998, 0.9988, and 0.9994 for acyclovir, amantadine, and oseltamivir, respectively.